 Corbus Pharmaceuticals NASDAQ: CRBP recently received a number of ratings updates from brokerages and research firms: 6262020 Corbus Pharmaceuticals was upgraded by analysts at BidaskClub from a hold rating to a buy rating. 6192020 Corbus Pharmaceuticals had its buy rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a 28.00 price ... 